Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on Company activities for the quarter ending 31 March 2021 (Q1 FY2021).
Q1 highlights:
- A second clinical site was established for the Phase I HER2 Breast Cancer Study
- Initiation of research for prostate cancer imaging supported by CSIRO funds
- Secured new premises from November 2021 enabling increased manufacturing capabilities